398 related articles for article (PubMed ID: 18354498)
1. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Lagirand-Cantaloube J; Offner N; Csibi A; Leibovitch MP; Batonnet-Pichon S; Tintignac LA; Segura CT; Leibovitch SA
EMBO J; 2008 Apr; 27(8):1266-76. PubMed ID: 18354498
[TBL] [Abstract][Full Text] [Related]
2. MAFbx/Atrogin-1 controls the activity of the initiation factor eIF3-f in skeletal muscle atrophy by targeting multiple C-terminal lysines.
Csibi A; Leibovitch MP; Cornille K; Tintignac LA; Leibovitch SA
J Biol Chem; 2009 Feb; 284(7):4413-21. PubMed ID: 19073596
[TBL] [Abstract][Full Text] [Related]
3. eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Csibi A; Tintignac LA; Leibovitch MP; Leibovitch SA
Cell Cycle; 2008 Jun; 7(12):1698-701. PubMed ID: 18583931
[TBL] [Abstract][Full Text] [Related]
4. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.
Bodine SC; Baehr LM
Am J Physiol Endocrinol Metab; 2014 Sep; 307(6):E469-84. PubMed ID: 25096180
[TBL] [Abstract][Full Text] [Related]
6. Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy.
Iyer CC; McGovern VL; Wise DO; Glass DJ; Burghes AH
Neuromuscul Disord; 2014 May; 24(5):436-44. PubMed ID: 24656734
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo.
Lagirand-Cantaloube J; Cornille K; Csibi A; Batonnet-Pichon S; Leibovitch MP; Leibovitch SA
PLoS One; 2009; 4(3):e4973. PubMed ID: 19319192
[TBL] [Abstract][Full Text] [Related]
8. eIF3f: a central regulator of the antagonism atrophy/hypertrophy in skeletal muscle.
Sanchez AM; Csibi A; Raibon A; Docquier A; Lagirand-Cantaloube J; Leibovitch MP; Leibovitch SA; Bernardi H
Int J Biochem Cell Biol; 2013 Oct; 45(10):2158-62. PubMed ID: 23769948
[TBL] [Abstract][Full Text] [Related]
9. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.
Zhang G; Jin B; Li YP
EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090
[TBL] [Abstract][Full Text] [Related]
10. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N
Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.
Li YP; Chen Y; John J; Moylan J; Jin B; Mann DL; Reid MB
FASEB J; 2005 Mar; 19(3):362-70. PubMed ID: 15746179
[TBL] [Abstract][Full Text] [Related]
13. Pyropia yezoensis peptide PYP1‑5 protects against dexamethasone‑induced muscle atrophy through the downregulation of atrogin1/MAFbx and MuRF1 in mouse C2C12 myotubes.
Lee MK; Kim YM; Kim IH; Choi YH; Nam TJ
Mol Med Rep; 2017 Jun; 15(6):3507-3514. PubMed ID: 28393223
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
15. Urotensin II can Induce Skeletal Muscle Atrophy Associated with Upregulating Ubiquitin-Proteasome System and Inhibiting the Differentiation of Satellite Cells in CRF Mice.
Pan Y; Zhou T; Dong X; Wu L; Wang P; Wang S; Zhang A
Calcif Tissue Int; 2023 May; 112(5):603-612. PubMed ID: 36892588
[TBL] [Abstract][Full Text] [Related]
16. UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy.
Seaborne RA; Hughes DC; Turner DC; Owens DJ; Baehr LM; Gorski P; Semenova EA; Borisov OV; Larin AK; Popov DV; Generozov EV; Sutherland H; Ahmetov II; Jarvis JC; Bodine SC; Sharples AP
J Physiol; 2019 Jul; 597(14):3727-3749. PubMed ID: 31093990
[TBL] [Abstract][Full Text] [Related]
17. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass.
Rom O; Reznick AZ
Free Radic Biol Med; 2016 Sep; 98():218-230. PubMed ID: 26738803
[TBL] [Abstract][Full Text] [Related]
18. Imoxin prevents dexamethasone-induced promotion of muscle-specific E3 ubiquitin ligases and stimulates anabolic signaling in C2C12 myotubes.
Eo H; Reed CH; Valentine RJ
Biomed Pharmacother; 2020 Aug; 128():110238. PubMed ID: 32450522
[TBL] [Abstract][Full Text] [Related]
19. RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease.
Xiong J; Le Y; Rao Y; Zhou L; Hu Y; Guo S; Sun Y
Am J Respir Cell Mol Biol; 2021 May; 64(5):617-628. PubMed ID: 33689672
[TBL] [Abstract][Full Text] [Related]
20. Effect of dexamethasone on the expression of atrogin-1/MAFbx in chick skeletal muscle.
Nakashima K; Ishida A; Ijiri D; Ohtsuka A
Anim Sci J; 2016 Mar; 87(3):405-10. PubMed ID: 26279163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
